Nutlin-3a

Catalog No.S8059 Batch:S805905

Print

Technical Data

Formula

C30H30Cl2N4O4
Molecular Weight 581.49 CAS No. 675576-98-4
Solubility (25°C)* In vitro DMSO 100 mg/mL (171.97 mM)
Ethanol 100 mg/mL (171.97 mM)
Water Insoluble
In vivo (Add solvents to the product individually and in order)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution
5%DMSO 40%PEG300 5%Tween80 50%ddH2O

Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.

 10.000mg/ml (17.20mM) Taking the 1 mL working solution as an example, add 50 μL of 200 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to make it clear; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results. 
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Nutlin-3a ((-)-Nutlin-3), the active enantiomer of Nutlin-3, inhibits the p53/MDM2 interaction with IC50 of 90 nM in a cell-free assay. Nutlin-3a induces autophagy and apoptosis in a p53-dependent manner.
Targets
p53-MDM2 interaction [3]
(Cell-free assay)
90 nM
In vitro Nutlin-3a displaces p53 from the binding pocket of MDM2 and thereby releases p53 from inhibition and proteasomal degradation, leading to induction of its downstream targets, cell cycle arrest, and apoptosis. Seven days of incubation with 10 μM of this compound led to >90% inhibition of NIH3T3 cells’ growth[1]. This compound stabilizes and activates p53, and induces p21 expression in a dose-dependent manner[1]. It effectively depletes the S-phase compartment to 0.2-2% and increases the G1- and G2/M-phase compartments[1]. This chemical induces apoptosis in ~60% of SJSA-1 and MHM cells after 40 h, which increased further after 60 h (85% and 65%, respectively) [1].
In vivo Nutlin-3a suppresses xenograft growth in a dose-dependent fashion with the highest dose (200 mg/kg) showing a substantial tumor shrinkage [1]. This compound is a selective activator of the p53 pathway in vivo and highly efficacious against SJSA-1 osteosarcoma tumors[1]. Tumors with wild-type p53 and mdm2 gene amplification will respond best to therapy with this chemical.
Features Highly selective MDM2 inhibitor with a much lower effect on MDMX. Most effective on tumors with wild type p53.

Protocol (from reference)

Kinase Assay:[3]
  • Biacore studies

    Competition assays are performed on a Biacore S51. A Series S Sensor chip CM5 is derivatized for immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~ 200 response units (1 response unit corresponds to 1 pg of protein per mm 2). The concentration of MDM2 protein is kept constant at 300 nM. Test compounds are dissolved in DMSO at 10 mM and further diluted to make a concentration series of inhibitor in each MDM2 test sample. The assays are run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of this compound is calculated as a percentage of binding in the absence of this compound and IC50 is calculated using Microsoft Excel
Cell Assay:[2]
  • Cell lines

    OSA, T778, RMS13, U2OS, SaOS-2

  • Concentrations

    ~5 μM

  • Incubation Time

    120 h

  • Method

    SRB
Animal Study:[1]
  • Animal Models

    SJSA-1 xenograft

  • Dosages

    50, 100, 200 mg/kg twice daily

  • Administration

    oral

References

  • https://pubmed.ncbi.nlm.nih.gov/16443686/
  • https://pubmed.ncbi.nlm.nih.gov/21624110/
  • https://pubmed.ncbi.nlm.nih.gov/14704432/

Customer Product Validation

<p>Nutlin-3a preserved p53 expression without influencing high glucose (HG)-induced podocyte impairment. A-D: cultured podocytes were pre-treated by nutlin-3a for 2 hrs before subjected to HG treatment. Western blotting gel documents (A) and summarized data (B) showing the expression of p53 and MDM2 in podocytes under HG exposure for 24 hrs. n = 4. Western blotting gel documents (C) and summarized data (D) showing the expression of Desmin in podocytes under HG exposure for 24 hrs. n = 3. *P < 0.05 vs. Ctrl, #P < 0.05 vs. Vehl + HG. Ctrl: control; Vehl: vehicle; nutlin-3a: nutlin-3a treatment.</p>

, , J Cell Mol Med, 2017, 21(12):3435-3444

Twenty-four hours after plating 1×105 Shh-EGFP cells, media was changed to serum-free media containing vehicle, 8µM Nutlin-3a, and/or Shh (3µg/mL). Cells were also transduced with lentivirus containing pLKO.1 empty vector or LentiORF-YFP-WIP1. 48 hours later, cells were fixed in 4% paraformaldehyde, permeabilized, incubated with α-WIP1 or α-Ki-67 antibody, and mounted using media containing DAPI. Scale bar, 100µm.

Data from [ , , Oncogene, 2016, 35(42):5552-5564 ]

(a) Westernblot analysis of the whole cell lysate from WT-MTEC, KO-MTEC and 1601 treated with or without Nutlin-3a (15 μM for MTEC) with antibodies as indicated.

Data from [ , , Int J Cancer. 2019, 144(4):777-787 ]

Protein expression of p53, TAZ and CYP24A1 were detected by western blot after treatment with Nutlin 3a in CCLP-1.

Data from [ , , Cancer Lett, 2016, 381(2):370-9 ]

Selleck's Nutlin-3a Has Been Cited by 121 Publications

A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 on chromatin [ Nucleic Acids Res, 2025, 53(13)gkaf627] PubMed: 40626562
Combined MEK and PARP inhibition enhances radiation response in rectal cancer [ Cell Rep Med, 2025, 6(8):102284] PubMed: 40782795
Chaperone-mediated autophagy directs a dual mechanism to balance premature senescence and senolysis to prevent intervertebral disc degeneration [ Bone Res, 2025, 13(1):62] PubMed: 40506462
WIP1 mutations suppress DNA damage triggered bypass of the mitotic timer [ EMBO J, 2025, 10.1038/s44318-025-00495-0] PubMed: 40551011
Advanced organoid models for targeting Kras-driven lung adenocarcinoma in drug discovery and combination therapy [ J Exp Clin Cancer Res, 2025, 44(1):128] PubMed: 40275403
The Prolonged Half-Life of the p53 Missense Variant R248Q Promotes Accumulation and Heterotetramer Formation with Wildtype p53 to Exert the Dominant-Negative Effect [ Cancer Res, 2025, 10.1158/0008-5472.CAN-24-1136] PubMed: 40163352
HOXC10 Protects from Skin Aging by Targeting the FZD6/Wnt/β-Catenin Signaling Pathway [ Research (Wash D C), 2025, 8:0976] PubMed: 41268215
Identification of CNOT1-CCR4-NOT as a suppressor of 53BP1-p53-p21 signaling [ Cell Rep, 2025, 44(8):116090] PubMed: 40742806
The puzzling regulation of the interferon signaling system by the p53 tumor suppressor protein [ Cell Mol Life Sci, 2025, 82(1):233] PubMed: 40512405
Reduction of lymphotoxin beta receptor induces cellular senescence via the MDMX-p53 pathway [ Cell Death Discov, 2025, 11(1):416] PubMed: 40883295

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.